Gsk Plc (GSK.LN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2000 | 12-1999 | 12-1998 | 12-1997 | 12-1996 | |
| Sales | 18,079,000 | 8,490,000 | 7,983,000 | 7,980,000 | 8,341,000 |
| Cost of Goods | 3,962,000 | 4,334,000 | 1,545,000 | N/A | N/A |
| Gross Profit | 14,117,000 | 4,156,000 | 6,438,000 | N/A | N/A |
| Operating Expenses | 10,696,000 | 1,357,000 | 3,784,000 | 5,083,000 | 5,214,000 |
| Operating Income | 3,421,000 | 2,799,000 | 2,654,000 | 2,897,000 | 3,127,000 |
| Interest Expense | 317,000 | 206,000 | 202,000 | 227,000 | 276,000 |
| Other Income | 2,925,000 | -18,000 | 219,000 | 16,000 | 113,000 |
| Pre-tax Income | 6,029,000 | 2,575,000 | 2,671,000 | 2,686,000 | 2,964,000 |
| Income Tax | 1,747,000 | 746,000 | 815,000 | 819,000 | 933,000 |
| Net Income Continuous | 4,282,000 | 1,829,000 | 1,856,000 | 1,867,000 | 2,031,000 |
| Minority Interests | -120,000 | -18,000 | -20,000 | -17,000 | -34,000 |
| Net Income | $4,162,000 | $1,811,000 | $1,836,000 | $1,850,000 | $1,997,000 |
| EPS Basic Total Ops | 0.85 | 0.63 | 0.64 | 0.65 | 0.71 |
| EPS Basic Continuous Ops | 0.85 | 0.63 | 0.64 | 0.65 | 0.71 |
| EPS Diluted Total Ops | 0.84 | 0.62 | 0.63 | 0.64 | 0.71 |
| EPS Diluted Continuous Ops | 0.84 | 0.62 | 0.63 | 0.64 | 0.71 |
| EBITDA(a) | $7,108,000 | $3,209,000 | $3,231,000 | $3,286,000 | $3,650,000 |